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A B ST R AC T 
 
 
Similar to the already well-recognized adenoma-carcinoma sequence in 
colorectal cancer pathogenesis, it has been believed for many decades 
that the progression of ovarian epithelial tumors occurs from benign 
serous cystadenomas to borderline tumors, to well-differentiated 
carcinomas, and ultimately, to poorly differentiated carcinomas. 
However, it is currently accepted that low-grade serous carcinoma 
(LGSC) and high-grade serous carcinoma (HGSC) are fundamentally 
different tumor types and, consequently, different diseases. In fact, 
whereas the benign-borderline-malignant sequence seems to apply quite 
well to low-grade serous carcinoma, the sequence of genetic alterations 
in high-grade serous carcinoma is substantially different. 
In this mini-review, we included the current consensus regarding the 
morphological and etiopathogenic results regarding serous tumors of the 
ovary, fallopian tube and peritoneum. It also briefly describes the history 
of benign, borderline and malignant serous tumors, discussing multiple 
types of dichotomies in serous carcinomas of the female genital tract and 
summarizing the current molecular classification.   
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Epithelial tumors of the ovary account for 
approximately two-thirds of all ovarian tumors in the 
Western world. They encompass a heterogeneous group of 
neoplasms that are primary classified based on the cell type 
into serous, mucinous, endometrioid, clear cell, transitional 
and squamous cell tumors. Based on the fact that the 
histologically normal counterparts of these cells are not 
usually present in the ovary, their neoplastic presence has 
previously been associated with müllerian neometaplasia 
of the ovarian surface epithelium (mesothelium), which 
evolves from celomic epithelium. Recently, several 
scientific studies have provided compelling evidence that 
multiple tumors, which were believed to be primary 
ovarian cancers, actually originate in other pelvic organs 
and involve the ovary as a secondary effect. As a matter of 
fact, novel molecular developments demonstrated that 
high-grade serous carcinomas might arise from precursor 
lesions in the epithelial lining of the distal fimbria of the 
fallopian tube, while endometrioid and clear cell 
carcinomas originate from ovarian endometriosis [1-3].  
The difference between borderline tumors and 
carcinomas is one of the most common problems in ovarian 
tumor pathology, yet the literature on borderline tumors is 
confusing, particularly with regard to their diagnostic 
features and treatment. Although the World Health 
Organization recommends the presence of “obvious 
invasion” of the stroma as a mandatory criterion for 
carcinoma, most pathologists do not require obvious 
stromal invasion for the diagnosis if the epithelial cells 
feature malignant cytology. In order to address this issue, 
the World Health Organization has proposed that such 
tumors be classified as borderline serous tumors with 
intraepithelial carcinoma. However, the heterogeneity of 
ovarian tumors and high inter-observer variability remain 
a difficult aspect in gynecological pathology [4-6]. 
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A thorough search on PubMed using various 
combinations of the following headings: “ovarian serous 
tumor”, “fallopian serous tumor”, “peritoneal serous 
tumor”, “serous borderline tumor”, “low-grade serous 
tumor” and “high-grade serous tumor” revealed a total of 
94 meta-analyses and systematic reviews published in the 
past 10 years. After thoroughly covering these 
publications, we have established a mini-review including 
the current consensus regarding the morphological and 
etiopathogenic results regarding serous tumors of the 
ovary, fallopian tubes and peritoneum [5]. 
Discussions 
Benign serous tumors of the ovary and fallopian tube   
Benign serous tumors are typically unilateral tumors, 
histologically composed of varying amounts of ovarian-
type stroma and benign tubal-type epithelium. Based on the 
predominant histological component, they can be classified 
into: serous cystadenoma (predominantly cystic, with 
minimal stromal component), serous cystadenofibroma 
(predominantly cystic, with abundant stromal component), 
serous adenofibroma (predominant stromal component 
admixed with small glands) and surface papilloma 
(adenofibroma variant with prominent papillae involving 
the ovarian surface) [1-3].  
Benign serous tumors have a wide age distribution, 
usually being diagnosed in the 4th decade. They can be 
asymptomatic or present with pelvic pressure and pain, 
urinary bladder symptoms or change in bowel habits due to 
secondary compression [2]. They can be treated by 
cystectomy or oophorectomy and have excellent 
prognoses. 
The ultrasound examination of the ovarian serous 
cystadenoma usually reveals a unilocular cystic or 
anechoic adnexal lesion, with no papillary projections. If 
any wall irregularity is present, it is thin, with regular 
surface and forms an acute angle with the cyst wall. Some 
lesions may contain ultrasonographically detectable 
septations, but with no flow on color Doppler. Almost all 
cystadenofibromas are predominantly cystic with 
septations seen in approximately 30% of the cases. 
Papillary projections or solid nodules have been 
ultrasonographically reported in just over 50% of the cases 
[1-4]. Vascularization can be present in less than 50% of 
cases, with a typical pattern of peripheral vascularization, 
with scattered vessels of high blood flow impedance. 
The gross features of benign serous tumors can vary 
widely, based on the morphological subtype. Most of them 
are unilateral, with a mean size of 8-9 cm. Serous 
cystadenomas are more frequently unilocular rather than 
multilocular, with clear to straw-colored fluid, minimal 
stromal component and smooth inner and outer surfaces. 
Some cysts have thick walls and may show internal folds 
when the cyst is collapsed. Serous cystadenofibromas 
present as variably sized cysts with white-to-gray, firm, 
solid areas, containing clear fluid. Firm papillary 
excrescences may sometimes be present on the surface. 
Serous adenofibromas are predominantly solid, firm, with 
white-to-grey homogenous cut surface and scattered small 
cysts filled with serous and/or serosanguineous fluid. 
Occasionally, serous adenofibromas only involve the 
ovarian surface as firm, nodular excrescences (surface 
serous papilloma) [5]. 
Histologically, benign serous tumors are composed of 
varying amounts of cysts, glands or papillae lined by a 
single layer of serous-type epithelium (cuboidal, columnar 
or flattened cells with variable amounts of cilia). 
Cystadenofibromas have variably cellular fibromatous 
stroma, which may feature areas of edema or hyalinization. 
Rarely, psammoma bodies, minor sex cord-like elements, 
signet ring stromal elements or ulceration with histiocytes 
may be present [6,7]. 
Immunohistochemically, PAX8, WT1 and ER are 
positive in the epithelial component and genetic testing 
may reveal copy number changes (trisomy 12) in stromal 
cells [8]. 
The differential diagnosis of benign serous tumors 
includes serous borderline tumors, endometriosis, 
peritoneal inclusion cysts, hydrosalpinx, cystic struma 
ovarii and rete cystadenoma [9].  
Serous borderline tumors of the ovary and fallopian 
tubes 
There are two histological types of serous borderline 
tumors: conventional and micro-papillary. Conventional 
serous borderline tumors are epithelial neoplasms 
composed of papillae with hierarchical branching lined by 
fallopian tube-type epithelium showing stratification, 
detached cell clusters, and low-grade nuclear atypia 
without evidence of frank stromal invasion [10]. Micro-
papillary serous borderline tumors are epithelial neoplasms 
in which papillae show abrupt transition from central 
fibrovascular cores to long, slender papillae which are 
usually five-times longer than wider, lined by cuboidal 
tubal-type epithelium without evidence of frank stromal 
invasion [11-13]. 
Serous borderline tumors represent 4% of all ovarian 
tumors and 10-15% of all ovarian serous tumors. The mean 
age at presentation is 42-50 years [14]. Most patients are 
asymptomatic, while others may present with abdominal 
pain, distention or ascites [15]. 
Serous borderline tumors are usually larger than 5 cm 
and frequently bilateral, especially the micro-papillary 
variant. They show velvety projections and/or nodularity, 
which are white-to-yellow, soft, friable and most of the 
times intracystic, with or without surface involvement. The 
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cystic space is filled with viscous or serous fluid and 
hemorrhage or necrosis are typically absent [16]. 
The histological architecture of conventional serous 
borderline tumors shows hierarchical branching of papillae 
with irregular contours, ending with detached cell clusters 
and single cells (budding/tufting). The wall of the cyst is 
composed of variable amounts of fibromatous stroma, 
which may show ulceration, hemosiderin deposition and 
foamy histiocytes [17]. Cytologically, the fibrovascular 
cores are lined by non-stratified or pseudostratified 
columnar or cuboidal cells, with low-grade nuclear atypia 
and small nucleoli. The cells may be ciliated or show clear 
or focal apical mucinous cytoplasm. Pregnant patients may 
also have variable numbers of polygonal and hobnail cells 
with eosinophilic cytoplasm. The histological architecture 
of micro-papillary serous borderline tumors is 
characterized by a central edematous papilla with abrupt 
transition to delicate, filiform micro-papillae without 
fibrovascular cores, which are five-times longer than 
wider. This structure is often referred to as “caput 
medusae”. Sometimes, the fusion of the micro-papillae can 
lead to a cribriform appearance [18]. Cytologically, the 
cells are cuboidal, with small, uniform nuclei, often with 
prominent nucleoli, high nuclear to cytoplasmic ratio and 
typical lack of cilia. 
Conventional and micro-papillary patterns may be 
admixed. In order to fall into the micro-papillary category, 
micro-papillary patterns must measure more than 5 mm in 
continuous extent or represent at least 10% of the tumor. If 
these criteria are not met, the tumor should be classified as 
serous borderline tumor with focal micro-papillary features 
[19]. 
Serous borderline tumors may show foci of 
microinvasion, noninvasive epithelial or desmoplastic 
implants, invasive implants and even lymph node 
involvement. 
Microinvasion is present in 10% of all serous 
borderline tumors and may show multiple histological 
patterns, which can coexist within the same tumor. 
Microinvasion is characterized by single cells, clusters of 
cells or small papillae floating in cleft-like spaces. 
Sometimes, this so-called “inside-out pattern” may 
represent lymphatics. In this case, immunohistochemistry 
for D2-40 can be useful. The area of microinvasion must 
measure less than 10 mm2 or less than 5 mm in its greatest 
extent. If the area is larger, the tumor should be classified 
as low-grade serous carcinoma [20]. 
Peritoneal implants are present in 30% of all serous 
borderline tumors [13,21]. They are more frequent in 
patients who have an exophytic component than in those 
that do not. Non-invasive implants are confined to the 
surface of organs. Non-invasive epithelial implants appear 
on peritoneal surfaces, as papillary proliferations or 
detached clusters of cells resembling those in ovarian SBT, 
confined within well demarcated cystic spaces or 
invaginations, lined by a single layer of serous cells. They 
are frequently associated with psammomatous 
calcifications. Non-invasive desmoplastic implants appear 
on peritoneal surfaces or ovarian surface (autoimplants) as 
single cells, clusters of cells, small papillae, or irregularly 
shaped glands with mild cytologic atypia, entrapped in a 
desmoplastic or granulation tissue-like stroma, which is the 
predominant component. They are also well demarcated 
from the underlying tissues. Invasive implants appear as 
small papillae, micro-papillae, small and large irregular 
glands, solid nests or single cells with destructive invasion 
of underlying tissues and desmoplastic response [22]. 
Lymph node involvement in patients with ovarian 
serous borderline tumors varies between 20% to 30%. 
However, most clinical studies with follow-up data 
indicate that the lymph node status is not an independent 
prognostic factor for the patient’s survival [23]. 
Serous borderline tumors show positive 
immunoreaction for CK7, PAX8, CA125, WT1, ER and 
PR [24]. Calretinin and p16 can be patchy positive or 
negative and p53 shows a wild-type pattern of expression 
(scattered positive cells) [25,26]. Genetic testing reveals 
BRAF and KRAS mutations with 95% concordance in 
serous borderline tumors and associated implants [27,28]. 
The differential diagnosis includes serous cystadenoma 
with focal epithelial proliferation, low-grade serous 
carcinoma, high-grade serous carcinoma, seromucinous 
borderline tumor, endometrioid borderline tumor, clear cell 
carcinoma, retiform variant of Sertoli-Leydig cell tumor, 
peritoneal low-grade serous carcinoma and 
endosalpingiosis [28-31]. 
The serous borderline tumor of the peritoneum 
The serous borderline tumor of the peritoneum is a low-
grade epithelial neoplasm of tubal-type cells with cellular 
proliferation and stratification, without underlying tissue 
invasion. For a serous borderline tumor to be designated as 
primary peritoneal, the ovaries must be grossly and 
microscopically normal or enlarged only by benign 
processes [32].  
Serous borderline tumors of the peritoneum are rare, 
with a peak incidence between the 4th and the 5th decades 
of life, have no association with BRCA1 or BRCA2 
mutations and most commonly affect the pelvis or both the 
pelvis and the abdominal cavity. 
Clinically, patients may present with pelvic pain, 
pressure, discomfort, ascites, vaginal bleeding or 
infertility, but most serous borderline tumors are usually 
asymptomatic and detected incidentally. Occasionally, 
they can be identified upon imaging investigations due to 
the presence of psammoma bodies in the Papanicolau 
smear [33,34].   
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The treatment involves hysterectomy with bilateral 
salpingo-oophorectomy with removal of any 
pelvic/omental tumor. If fertility is desired, the 
conservative approach may be considered. At the time of 
writing, chemotherapy or radiation have no established role 
in the therapeutic management of serous borderline tumors 
of the peritoneum. Most tumors have a favorable 
prognosis, but recurrences are common. If these tumors 
progress to serous carcinomas, adverse outcomes are very 
likely and most patients die from the disease. 
Grossly, serous borderline tumors of the peritoneum 
appear as adhesions simulating the inflammatory pelvic 
disease with individual nodules smaller than 1 cm. 
From a histopathological point of view, serous 
borderline tumors resemble non-invasive or desmoplastic 
implants of ovarian serous borderline tumors and are 
composed of papillae, nests, glands, clusters of cells or 
single cells with tufting, budding and epithelial pseudo-
stratification. The cells are uniform, cuboidal or columnar, 
with eosinophilic cytoplasm and round nuclei, with small 
nucleoli [35]. 
The differential diagnosis includes primary peritoneal 
low-grade serous carcinoma, non-invasive implants of 
ovarian serous borderline tumor, well-differentiated 
papillary mesothelioma or malignant mesothelioma and 
endosalpingiosis with focal atypia [36-38]. 
Low-grade serous carcinomas of the ovary and 
fallopian tubes  
The low-grade serous carcinoma is a malignant 
epithelial neoplasm of serous cell lineage with distinctive 
architecture, low-grade nuclear atypia and destructive 
invasion. 
Low-grade serous carcinoma is less frequent than high-
grade serous carcinoma, accounting for 3.5% of all ovarian 
carcinomas and 5% of all serous carcinomas [39]. It usually 
affects patients in the 6th decade of life and it can be 
diagnosed incidentally or present with abdominal swelling 
or pain. Low-grade serous carcinomas are usually high 
stage at presentation and may be a recurrence of a previous 
serous borderline tumor. Most tumors tend to have an 
indolent course with progressive disease. The therapeutic 
management involves bilateral salpingo-oophorectomy 
and hysterectomy with debulking and staging biopsies. 
Imaging techniques play an important role in the 
diagnosis of ovarian carcinoma and in the assessment of 
the metastatic disease. However, surgical and 
histopathological examinations remain the standard of care 
for staging the disease [40]. Typical imaging features of 
ovarian serous carcinomas include: the presence of a cystic 
adnexal mass with substantial solid components, 
associated with ascites, peritoneal nodularity and 
lymphadenopathy. Calcification can be seen in 
approximately 12% of the cases, but it also appears in 
serous cystadenoma and other tumors [41]. 
Low-grade serous carcinomas are typically bilateral, 
solid or both solid and cystic with multiple polypoid 
excrescences and little, if any, necrosis. Solid areas may 
have gritty surfaces due to calcifications. Most tumors 
show a non-invasive serous borderline component, with or 
without a micro-papillary pattern [42]. 
The histological examination of low-grade serous 
carcinomas will reveal both non-invasive and invasive 
patterns [43]. Non-invasive patterns are represented by tall 
and slender to rounded bud-like papillae with variable 
cellularity as well as solid, fenestrated or cribriform areas 
of epithelial proliferation. Cytologically, the cells show 
low-grade nuclear atypia with prominent nucleoli. Invasive 
patterns must measure more than 5 mm in continuous 
extent and may be represented by micro-papillae, small 
papillae, small or large nests or inverted micro-papillae in 
cleft-like spaces. Rarely, single cells, signet cells, solid, 
cribriform or glandular patterns of growth may show 
haphazard invasion and desmoplastic stromal reaction. 
Psammoma bodies are common and variably numerous. 
Necrosis and cytological pleomorphism are rare [44]. 
The immunohistochemical profile of low-grade serous 
carcinoma is very similar to that of its high-grade 
counterpart [45]. The only significant differences are wild-
type pattern of expression for p53 and lower Ki67 index in 
low-grade serous ovarian carcinomas. B-RAF and K-RAS 
mutations are present in 38% and 19% of cases, 
respectively [46]. Low-grade serous carcinomas do not 
show chromosomal instability and lack the complex 
genetic abnormalities seen in high-grade serous 
carcinomas. Moreover, low-grade serous carcinomas are 
not associated with BRCA germline mutations [47,48]. 
The differential diagnosis of low-grade serous ovarian 
carcinoma includes high-grade serous carcinoma, serous 
borderline tumor, endometrioid borderline tumor and 
malignant mesothelioma secondarily involving the ovary. 
High-grade serous carcinomas of the ovary and 
fallopian tubes 
The high-grade serous carcinoma is a malignant 
epithelial tumor showing serous (tubal-type) 
differentiation with papillary, solid and/or glandular 
growth and moderate to severe nuclear atypia [49]. 
The high-grade serous ovarian carcinoma is the most 
common type of ovarian cancer, accounting for 
approximately 70% of all ovarian carcinomas. It usually 
affects slightly older women than the low-grade serous 
ovarian carcinoma (the 6th to the 7th decade of life) [50]. 
Although most patients have symptoms, these are often 
subtle or nonspecific and easily confused with those of 
benign conditions of the gastrointestinal and urinary tracts. 
Because of this, up to 80% of the patients present with 
advanced stage disease and tumors confined to the ovary at 
diagnosis are extremely uncommon. The clinical features 
include pelvic pain, gastrointestinal symptoms, increased 
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abdominal girth due to ascites, urinary frequency, dysuria 
and vaginal bleeding [51]. 
High grade serous ovarian carcinomas range in size 
from microscopic to over 20 cm in diameter and are 
bilateral in 60% of all cases. The papillae tend to be softer 
and more confluent than those in serous borderline tumors. 
Poorly differentiated tumors are predominantly solid, 
multinodular masses with extensive areas of necrosis and 
hemorrhage [52]. 
Histologically, high-grade serous ovarian tumors show 
multiple architectural patterns, frequently admixed, 
including: hierarchical branching of variably sized papillae 
with cellular tufting and budding, bridging and fusion of 
papillae with formation of slit-like spaces, solid, pseudo-
endometrioid, transitional cell carcinoma-like, 
microcystic, glandular or micro-papillary patterns [53,54]. 
Cytologically, the proliferation is composed of columnar 
to cuboidal epithelial cells with variable amounts of 
eosinophilic and sometimes clear cytoplasm, showing 
high-grade nuclear atypia, often with severe pleomorphism 
and more than 3-fold variation in nuclear size. Necrosis is 
frequent and extensive. The mitotic index is high 
(typically >12 mitoses / 10HPF), with mostly atypical 
forms. Solid, pseudo-endometrioid and transitional cell 
carcinoma-like morphology, as well as tumor infiltrating 
lymphocytes are more common in patients with BRCA1 
mutation, but these features are not pathognomonic of that 
setting. Psammoma bodies can be present, but are less 
numerous than in low-grade serous ovarian carcinomas. If 
sampled accordingly, most high-grade serous ovarian 
carcinomas will reveal the association with serous tubal 
intraepithelial carcinoma. Although low-grade and high-
grade serous ovarian carcinoma typically develops 
independently, in some cases, a morphologic continuum 
may be seen. 
The assignment of primary site for high-grade serous 
carcinoma (ovary vs. fallopian tube vs. peritoneum) is 
arbitrary and has no clinical relevance. Singh et al. 
proposed the following scheme for assigning the site of 
origin: primary ovarian for dominant ovarian masses 
without serous tubal intraepithelial carcinoma and primary 
tubal for dominant ovarian masses with serous tubal 
intraepithelial carcinoma [51,52]. 
Most high-grade serous carcinomas show either diffuse 
positivity or complete absence of p53 and strong and 
diffuse staining for p16 in approximately 60% of the cases. 
Ki67 is usually > 75% and Napsin-A and HNF-1β are 
negative [53, 54]. 
The differential diagnosis includes low-grade serous 
carcinoma, clear cell carcinoma, undifferentiated 
carcinoma, endometrioid carcinoma, metastatic serous 
carcinoma, metastatic breast carcinoma and malignant 
mesothelioma [55-58]. 
Serous carcinomas of the peritoneum 
The serous carcinoma of the peritoneum is a malignant 
neoplasm showing tubal-type differentiation. For a serous 
carcinoma to be designated as primary peritoneal, the 
ovaries and fallopian tubes must be grossly and 
microscopically normal or altered only by benign 
processes and no evidence of primary ovarian, tubal or 
uterine serous carcinoma (including serous intraepithelial 
carcinoma) should be found [59]. 
Both low-grade and high-grade serous carcinomas of 
the peritoneum are extremely rare, with a continuously 
decreasing incidence due to the increased recognition of 
fallopian tube primary tumors. Low-grade serous 
carcinomas usually affect patients in the 5th decade of life, 
while high-grade serous carcinomas appear 2 decades later. 
Symptoms, if present, can include malaise, increasing 
girth, changes in bowel habits and abdominal pain [60]. 
Low-grade serous carcinomas of the peritoneum have a 
relatively indolent course, but they are usually 
chemoresistant. On the other hand, high-grade serous 
carcinomas are initially chemosensitive, but recur 
frequently. The therapeutic management involves 
hysterectomy with bilateral salpingo-oophorectomy, 
omentectomy and the surgical removal of any 
macroscopically visible tumor, followed by platinum 
chemotherapy [61]. 
Conclusions 
Ovarian cancer remains the most lethal neoplasm in 
gynecological oncological pathology and malignant 
epithelial tumors are the most common subtype, 
accounting for 90% of the cases. Although traditionally 
referred to as a single entity, ovarian cancer is not a 
homogenous disease but rather a group of diseases with 
variable morphology and biologic behavior. Based on the 
histopathological, immunohistochemical and molecular 
genetic analyses, there are at least five subtypes of ovarian 
carcinomas: high-grade serous carcinomas, endometrioid 
carcinomas, clear cell carcinomas, mucinous carcinomas 
and low-grade serous carcinomas. These tumors account 
for 98% of the ovarian carcinomas, can be reproducibly 
diagnosed by light microscopy and are inherently different 
diseases, as indicated by differences in epidemiologic and 
genetic risk factors, precursor lesions, patterns of spread, 
molecular events during oncogenesis, response to 
chemotherapy and prognosis.   
In this review, we briefly described the history of 
benign, borderline and malignant serous tumors, discussed 
multiple types of dichotomies in serous carcinomas of the 
female genital tract and summarized the current molecular 
classification. Although traditionally, ovarian tumors were 
diagnosed based on morphology alone, the current 
concepts have shifted to a combination of histologic and 
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molecular findings. While the importance of 
histopathological examination in unravelling the origins of 
high-grade serous carcinoma is undeniable, future 
molecular findings could rank at the top of an integrated 
diagnosis system for making a decision.  
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